+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast 2026-2032- Product Image
Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast 2026-2032- Product Image
Sale

Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532737
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Deep Brain Stimulation in Parkinson’s Disease Market is projected to reach USD 1.61 Billion in 2026. It is expected to continue growing at a CAGR of 16.15%, reaching USD 4.02 Billion by 2032.

Deep brain stimulation (DBS) in Parkinson’s disease is a high-value neuromodulation field serving patients with medication-refractory motor fluctuations, dyskinesia, or tremor. The therapy is supported by decades of clinical use, randomized evidence, and guideline-based patient selection, with common surgical targets including the subthalamic nucleus, globus pallidus internus, and, for tremor-dominant cases, the ventral intermediate nucleus.

Market momentum is grounded in verified epidemiology: the World Health Organization reports that Parkinson’s disease prevalence has doubled over the past 25 years, with more than 8.5 million people living with the condition globally in 2019. For DBS device manufacturers, the opportunity is shifting from one-time implant sales toward integrated deep brain stimulation platforms combining directional leads, rechargeable implantable pulse generators, imaging-based planning, remote support, and data-enabled programming workflows.

Transformative Shifts in the DBS Landscape

The DBS landscape is being transformed by precision targeting, segmented electrodes, longer-life batteries, sensing-enabled pulse generators, and improved imaging-guided surgical planning. These shifts are improving therapeutic windows, reducing programming burden, and allowing manufacturers to differentiate through clinical workflow efficiency, patient durability, and long-term outcomes rather than hardware alone.

Regulatory expectations are also becoming more demanding. The U.S. FDA, the European Medical Device Regulation framework, and other major regulators increasingly emphasize post-market evidence, cybersecurity, software validation, human factors, and real-world performance. Companies that align product design with clinical usability, payer evidence, and long-term safety monitoring are better positioned in the Parkinson’s disease neuromodulation market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across DBS product development, surgical planning, and post-implant optimization. Machine learning is being evaluated for imaging segmentation, lead localization, symptom-state estimation, and parameter recommendation, while adaptive DBS research uses neural signals such as local field potentials to adjust stimulation in response to changing patient states.

The commercial impact remains evidence-dependent. AI-enabled DBS tools must demonstrate clinical validity, bias control, explainability, cybersecurity resilience, and compliance with software-as-a-medical-device requirements. Manufacturers that develop AI as a clinician-supervised decision-support layer, rather than an autonomous replacement for neurologist expertise, are most aligned with current regulatory and clinical standards.

Key Regional Insights for DBS in Parkinson’s Disease

North America remains a leading region for DBS adoption because of specialized movement disorder centers, established reimbursement pathways, FDA-cleared neuromodulation platforms, and robust clinical trial infrastructure. Europe combines strong clinical expertise with the more rigorous European Medical Device Regulation, making evidence generation, vigilance, and health technology assessment essential for market access across national health systems.

Asia-Pacific is becoming a strategic growth region as Japan, South Korea, China, Australia, and India expand advanced neurology and neurosurgery capacity alongside rapidly aging populations and rising Parkinson’s disease diagnosis. Latin America shows demand in Brazil, Mexico, and major urban hospital systems but faces affordability, reimbursement, and specialist-density constraints. The Middle East, particularly high-investment Gulf health systems, is expanding advanced care and tertiary neuroscience services, while Africa remains access-limited outside select tertiary centers, creating a long-term need for training, referral pathways, and cost-sensitive DBS technologies.

Key Group Insights Across Strategic Economic Blocs

The G7 represents the most mature demand environment for DBS device manufacturers because member countries generally combine aging populations, high specialist capacity, advanced imaging infrastructure, clinical trial networks, and established reimbursement evaluation systems. The European Union is strategically important due to scale and regulatory harmonization, although national purchasing, tendering, and health technology assessment processes continue to shape adoption country by country.

BRICS markets offer large patient pools and growing neurosurgical capacity, led by China, India, and Brazil, but pricing, reimbursement, and urban-rural access gaps remain decisive. ASEAN is heterogeneous, with Singapore, Thailand, and Malaysia supporting more advanced tertiary care than lower-resource markets, while capacity building remains central in several member states. The GCC is expanding premium specialty care through public investment and medical infrastructure development, while NATO is not a healthcare purchasing bloc but includes many countries with strong neuromodulation research, data-security expectations, and advanced hospital infrastructure.

Key Country Insights in Major DBS Markets

The United States anchors global DBS commercialization through FDA-regulated innovation, extensive movement disorder networks, specialized neurosurgical centers, and strong academic trial activity. Canada supports evidence-based adoption through provincial health systems, while Mexico and Brazil show concentrated demand in major metropolitan centers where private and public tertiary care can support complex neurosurgery and post-implant programming.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established DBS expertise, although reimbursement timing, hospital procurement, and regional access differ. Russia retains specialized neurosurgical capacity but faces broader market-access complexity. In Asia-Pacific, China is scaling domestic and international neuromodulation adoption, India combines high unmet need with affordability constraints, Japan and South Korea offer technologically advanced care with strong hospital infrastructure, and Australia benefits from specialized public and private centers serving geographically dispersed patients.

Actionable Recommendations for DBS Industry Leaders

Device leaders should prioritize differentiated clinical value: directional stimulation, battery longevity, simplified programming, MRI compatibility, remote support, patient-friendly rechargeability, and real-world outcome tracking. Evidence packages should address motor improvement, quality of life, adverse events, reoperation rates, programming time, medication reduction, patient satisfaction, and total cost of care.

Commercial teams should invest in surgeon-neurologist training, center-of-excellence partnerships, referral pathway development, and payer-ready health economics. AI-enabled features should be launched with transparent validation, clinician oversight, cybersecurity controls, interoperability planning, and post-market monitoring to build trust across regulators, hospitals, clinicians, and patients.

Research Methodology

This executive summary is based on triangulation of verified public evidence, including World Health Organization Parkinson’s disease epidemiology, peer-reviewed DBS clinical literature, Movement Disorder Society-aligned practice standards, regulator communications, and publicly available market-access information from major healthcare systems.

The analysis emphasizes evidence-backed drivers rather than speculative market sizing. Regional, group, and country insights were assessed through disease burden, aging demographics, neurosurgical capacity, reimbursement maturity, regulatory requirements, technology readiness, clinical infrastructure, and observed adoption patterns in advanced movement disorder care.

Conclusion

DBS remains one of the most established advanced therapies for appropriately selected Parkinson’s disease patients whose symptoms are not adequately controlled with medication. The market is moving toward precision neuromodulation platforms supported by better imaging, sensing, software, programming efficiency, and long-term evidence.

Manufacturers that combine clinically meaningful innovation with regulatory discipline, payer evidence, cybersecurity readiness, and scalable training infrastructure will be best positioned as Parkinson’s disease prevalence rises and health systems demand measurable outcomes from high-cost implantable therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Deep Brain Stimulation in Parkinson’s Disease Market, by Device Type
7.1. Introduction
7.2. Implantable Pulse Generators
7.2.1. Rechargeable IPGs
7.2.2. Non-rechargeable IPGs
7.3. Leads
7.3.1. Directional Leads
7.3.2. Omnidirectional Leads
7.4. Extension Kits
7.5. External Components
8. Deep Brain Stimulation in Parkinson’s Disease Market, by Target Stimulation Site
8.1. Introduction
8.2. Subthalamic Nucle
8.3. Globus Pallidus Internus
8.4. Thalamus
8.5. Pedunculopontine Nucleus
9. Deep Brain Stimulation in Parkinson’s Disease Market, by Implantation Type
9.1. Introduction
9.2. Unilateral DBS
9.3. Bilateral DBS
10. Deep Brain Stimulation in Parkinson’s Disease Market, by Patient Age Group
10.1. Introduction
10.2. Less than 60 years
10.3. 60-75 years
10.4. Greater than 75 years
11. Deep Brain Stimulation in Parkinson’s Disease Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Deep Brain Stimulation in Parkinson’s Disease Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Deep Brain Stimulation in Parkinson’s Disease Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Deep Brain Stimulation in Parkinson’s Disease Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Aleva Neurotherapeutics SA
16.3. Alpha Omega Engineering Ltd.
16.4. Beijing PINS Medical Co., Ltd.
16.5. Boston Scientific Corporation
16.6. BrainsWay Ltd.
16.7. Deep Brain Innovations LLC
16.8. Functional Neuromodulation, Ltd.
16.9. LivaNova PLC
16.10. Medtronic plc
16.11. Neuralink Corp.
16.12. Neuronetics, Inc.
16.13. NeuroPace, Inc.
16.14. NeuroSigma, Inc.
16.15. Newronika S.p.A.
16.16. PulseNeuro LLC
16.17. Renishaw PLC
16.18. Saluda Medical Pty Ltd.
16.19. Sapiens Neuro
16.20. SceneRay Corporation Ltd.
16.21. Shanghai Sinovation Medical Tech
16.22. Soterix Medical Inc.
16.23. St. Jude Medical, Inc.
List of Figures
FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL LEADS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL LEADS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL LEADS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL EXTENSION KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL EXTENSION KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL EXTENSION KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL THALAMUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL THALAMUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL THALAMUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL UNILATERAL DBS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL UNILATERAL DBS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL UNILATERAL DBS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BILATERAL DBS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BILATERAL DBS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BILATERAL DBS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL 60-75 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL 60-75 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL 60-75 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 85. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 95. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 96. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 97. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 98. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 99. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 100. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 111. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 112. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 113. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 114. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 115. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 116. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 120. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 121. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 122. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 123. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 124. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 125. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 128. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 129. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 130. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 131. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 132. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 133. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 144. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 145. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 146. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 147. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 148. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 149. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 152. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 153. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 154. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 155. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 156. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 157. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 160. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 161. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 162. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 163. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 164. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 165. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 172. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 174. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 176. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 177. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 178. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 179. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 180. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 181. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 182. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 184. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 185. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 186. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 187. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 188. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 189. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 190. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 194. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 195. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 196. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 197. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 198. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 209. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 210. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 211. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 212. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 213. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 214. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 217. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 218. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 219. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 220. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 221. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 222. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 225. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 226. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 227. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 228. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 233. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 234. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 235. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 236. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 237. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 238. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 241. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 242. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 243. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 244. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 245. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 246. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 249. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 250. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 251. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 252. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 253. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 254. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 257. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 258. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 259. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 260. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 261. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 262. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 265. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 266. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 267. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 268. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 269. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 270. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 281. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2017-2032 (USD MILLION)
TABLE 282. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2017-2032 (USD MILLION)
TABLE 283. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2017-2032 (USD MILLION)
TABLE 284. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 288. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Alpha Omega Engineering Ltd.
  • Beijing PINS Medical Co., Ltd.
  • Boston Scientific Corporation
  • BrainsWay Ltd.
  • Deep Brain Innovations LLC
  • Functional Neuromodulation, Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Neuralink Corp.
  • Neuronetics, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Newronika S.p.A.
  • PulseNeuro LLC
  • Renishaw PLC
  • Saluda Medical Pty Ltd.
  • Sapiens Neuro
  • SceneRay Corporation Ltd.
  • Shanghai Sinovation Medical Tech
  • Soterix Medical Inc.
  • St. Jude Medical, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.02 Billion
Compound Annual Growth Rate16.1%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Deep Brain Stimulation in Parkinson`s Disease Market Report 2026 - Product Image

Deep Brain Stimulation in Parkinson`s Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Deep Brain Stimulation Devices Market - Global Forecast 2026-2032 - Product Image

Deep Brain Stimulation Devices Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report - Product Image

Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Deep Brain Stimulation Devices Market Analysis (2026-2031): Neurotech Innovations, Supply Chain Dynamics, and Strategic Intelligence - Product Image

Deep Brain Stimulation Devices Market Analysis (2026-2031): Neurotech Innovations, Supply Chain Dynamics, and Strategic Intelligence

  • Report
  • 95 Pages
  • Global
From
Deep Brain Stimulation Devices - Global Strategic Business Report - Product Image

Deep Brain Stimulation Devices - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From

About the Deep Brain Stimulation In Parkinson Disease Market

Deep brain stimulation (DBS) for Parkinson's disease is a therapeutic procedure aimed at managing the symptoms of this neurodegenerative disorder when medication is insufficient or leads to undesirable side effects. This method involves the surgical implantation of electrodes within certain areas of the brain, generating electrical impulses that regulate abnormal impulses. The DBS devices are an integral part of the Central Nervous System (CNS) drugs and devices domain, which encompasses a broad range of therapies for various neurological conditions, including medication, neuromodulation devices, and support services. Within this context, DBS acts as an adjunct to pharmacological treatments, offering an alternative for patients with advanced Parkinson's disease. While CNS drugs typically address the dopaminergic deficits inherent to Parkinson's disease pathophysiology through oral or injectable medications, DBS provides a unique mechanistic approach by directly modulating brain activity and circuits involved in motor control. The procedure is generally reserved for patients exhibiting motor fluctuations and tremors that are not adequately controlled by medication. Several industry players are active in the DBS market for Parkinson's disease. Key companies engaged in the development and provision of DBS systems include Medtronic, Boston Scientific, and Abbott Laboratories. These entities continuously engage in research and development to advance the technology, increase its efficacy, and reduce any associated risks, thereby improving the lives of patients with Parkinson's disease. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.